Pulnovo Medical, a Shanghai, China-based provider of an OTM (From Operating Table to Market) platform, raised tens of millions dollars in funding.
The round was led by YuanBio Venture Capital, with participation from Orbimed Healthcare Fund Management, Cenova Capital, Lilly Asia Ventures, GaoRong Capital, Huihe Capital and GC&H Investments.
The company intends to use the funds to accelerate its Pulmonary Artery Denervation (PADN) FDA-Global Trial, expand the research and development capability in the cardiopulmonary disease treatment and execute its marketing and commercialization strategy.
Led by CEO Jessie Lian, Pulnovo Medical is a device pioneer in the treatment for cardiopulmonary diseases. Established in 2013, the company upholds evidenced-based research and translational medicine, and starts its research and development efforts alongside physicians at the operating table with the goal to market innovative therapeutic solutions for patients around the world.
The funding, an undisclosed amount totaling millions of dollars, will enable Pulnovo to accelerate its Pulmonary Artery Denervation (PADN) FDA-Global Trial, expand the research and development capability in the cardiopulmonary disease treatment and execute marketing and commercialization strategy.
PADN is expected to receive approval from China’s National Medical Products Administration (NMPA) for pulmonary arterial hypertension (PAH) treatment in the first quarter of 2023.
FinSMEs
07/11/2022